Systemic therapy for inoperable and metastatic basal cell cancer

Current Treatment Options in Oncology

Volumn 14, Issue 2, 2013, Pages 237-248

  Fecher, Leslie A ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Basal cell carcinoma; Basal cell nevus syndrome; Gorlin; Hedgehog; Nevoid basal cell carcinoma syndrome; Smoothened; Vismodegib

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BMS 833923; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GANT 61; ITRACONAZOLE; LEQ 506; METHOTREXATE; PACLITAXEL; PF 04449913; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; SARIDEGIB; SONIDEGIB; TAK 441; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VISMODEGIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASYMPTOMATIC DISEASE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CHEMOSURGERY; DECREASED APPETITE; DEHYDRATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; HAIR LOSS; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INOPERABLE CANCER; LIVER DYSFUNCTION; METASTASIS; MOLECULARLY TARGETED THERAPY; MUSCLE SPASM; MYALGIA; NAUSEA; NONHUMAN; PARANOIA; PHOTODYNAMIC THERAPY; PRESYNCOPE; PYELONEPHRITIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; SKIN CARCINOGENESIS; SOLID TUMOR; SYSTEMIC THERAPY; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS, BASAL CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84877732592     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0233-9     Document Type: Article

References (88)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-7.
2. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262-9.
3. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol. 1991;17(9):713-8.
4. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131:157-63.
5. Zhang M, Qureshi AA, Geller AC, et al. Use of tanning beds and incidence of skin cancer. J Clin Oncol. 2012;30(14):1588-93. Large cohort study that showed a dose-response relationship between indoor tanning and skin cancer, strongest for BCC.
6. Lear JT, Tan BB, Smith AG, et al. Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med. 1997;90(7):371-4.
7. Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54:189-206.
8. Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors and management. Derm Surg. 2012;38(10):1622-30.
9. Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For the skin cancer prevention study group. J Natl Cancer Inst. 1996;88(24):1848-53.
10. Castori M, Morrone A, Kanitakis J, et al. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol. 2012;22(3):299-309.
11. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine. 1987;66:98-113.
12. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995;13:113-25.
13. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69(1):111-7.
14. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841-51.
15. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668-71.
16. Lin TL, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets Ther. 2012;5:47-58.
17. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110:885-8.
18. Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1997;57(13):2581-5.
19. Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90-2.
20. Ling G, Ahmadian A, Persson A, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001;20:7770-8.
21. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152(1):43-51.
22. Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality: a population-based study. Arch Dermatol. 1991;127:1194-7.
23. Zoccali G, Pajand R, Papa P, et al. Giant basal cell carcinoma of the skin: literature review and personal experience. J Eur Acad Dermatol Venereol. 2012;26(8):942-52.
24. Ionescu DN, Arida M, Jukic D. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med. 2006;130:45-51.
25. Menz J, Sterrett G, Wall L. Metastatic basal cell carcinoma associated with a small primary tumour. Australas J Dermatol. 1985;26:121-4.
26. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64(6):1051-9.
27. Paver K, Poyzer K, Burry N, et al. Letter: the incidence of basal cell carcinoma and their metastases in Australia and New Zealand. Australas J Dermatol. 1973;14:53.
28. Mikhail GR, Nims LP, Kelly Jr AP, et al. Metastatic basal cell carcinoma: review, pathogenesis, and report of two cases. Arch Dermatol. 1977;113:1261-9.
29. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10:1043-60.
30. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24:715-9.
31. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma: report of five cases. Cancer. 1994;73:328-35.
32. Lattes R, Kessler RW. Metastasizing basal cell epithelioma of the skin: report of two cases. Cancer. 1951;4:866-78.
33. Niederkohr RD, Gamie SH. F-18 FDG PET as an imaging tool for detecting and staging metastatic basal cell carcinoma. Clin Nucl Med. 2007;32:491-2.
34. Raszewski RL, Guyuron B. Long-term survival following nodal metastases from basal cell carcinoma. Ann Plast Surg. 1990;24:170-5.
35. Ko CB, Walton S, Keczkes K. Extensive and fatal basal cell carcinoma: a report of three cases. Br J Dermatol. 1992;127:164-7.
36. Kovarik C, Stewart D, Barnard JJ. Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol. 2005;52:149-51.
37. Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3-4):389-402.
38. Siegle RJ, Wood T. Nonrecurrent primary basal cell carcinoma of the lower extremity with late metastasis. J Dermatol Surg Oncol. 1994;20(7):490-3.
39. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol. 1992;18(6):471-6.
40. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720-6.
41. Mulayim N, Silver DF, Ocal IT. Vulvar basal cell carcinoma: two unusual presentations and review of the literature. Gynecol Oncol. 2002;85:532-7.
42. Kinoshita R, Yamamoto O, Yasuda H, et al. Basal cell carcinoma of the scrotum with lymph node metastasis: report of a case and review of the literature. Int J Dermatol. 2005;44(1):54-6.
43. Dixon AY, Lee SH, McGregor DH. Histologic features predictive of basal cell carcinoma recurrence: results of a multivariate analysis. J Cutan Pathol. 1993;20(2):137-42.
44. Miller S, Alam M, Anderson J, et al. Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology. Version 2.2012.
45. Brown CI, Perry AE. Incidence of perineural invasion in histologically aggressive types of basal cell carcinoma. Am J Dermatopathol. 2000;22:123-5.
46. Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer. 1980;46:748-57.
47. Healy E, Angus B, Lawrence CM, et al. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol. 1995;133:737-41.
48. Bolshakov S, Walker CM, Strom SS, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res. 2003;9:228-34.
49. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;24(1):CD003412.
50. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992;18(7):549-54.
51. Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol. 2008;52(3):278-86.
52. Hartman R, Hartman S, Green N. Long-term survival following bony metastases from basal cell carcinoma. report of a case. Arch Dermatol. 1986;122:912-4.
53. Salem P, Hall SW, Benjamin RS, et al. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous IV infusion. Cancer Treat Rep. 1978;62:1553-5.
54. Woods RL, Stewart JF. Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgrad Med J. 1980;56:272-3.
55. Wieman TJ, Shively EH, Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. a case report. Cancer. 1983;52:1583-5.
56. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients. Arch Dermatol. 1990;126(12):1660.
57. Guthrie Jr TH, McElveen LJ, Porubsky ES, et al. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55(8):1629-32.
58. Guthrie Jr TH, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342-6.
59. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer. 1990;26:73-7.
60. Moeholt K, Aagaard H, Pfeiffer P, et al. Platinum-based cytotoxic therapy in basal cell carcinoma - a review of the literature. Acta Oncol. 1996;35:677-82.
61. Jefford M, Kiffer JD, Somers G, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004;74:704-5.
62. Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Investig. 2006;24(4):396-400.
63. Krahn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer. 2001;37:251-9.
64. Muller H, Eisendle K, Gastl G, et al. Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386-8.
65. Caron J, Dereure O, Kerob D, et al. Metastatic basal cell carcinoma: a report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702-3.
66. Kalapurakal SJ, Malone J, Robbins KT, et al. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257-61.
67. Chen JK, Taipale J, Cooper MK, et al. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002;16:2743-8.
68. Keeler RF. Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship, and biologic effects. Lipids. 1978;13(10):708-15.
69. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:5576-81.
70. Ding X, Chou B, Graham RA, et al. Determination of GDC-0449, a small molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction liquid chromatographic-tandem mass spectrometry. J Chromatogr B. 2010;878:785-90.
71. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164-72. Report of the BCC patient cohort treated on the phase I study of the first-in class SMO inhibitor, vismodegib, demonstrating good tolerability and significant clinical activity in advanced BCC.
72. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502-11. Report of the entire phase I study of vismodegib with updated efficacy data.
73. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
74. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9. Pivotal phase II study that evidenced responses in laBCC and mBCC to treatment with vismodegib in advanced BCC, including 21 % CR in laBCC.
75. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180-8. Phase II randomized, double-blind, placebo-controlled study of vismodegib in patients with NBCCS that demonstrated significant decrease in the development of new resectable BCCs as well as decrease in size of existing BCC. Of note, 54 % of patients came off study for toxicity.
76. Tawbi HA, Rodon Ahnert J, Dummer R, et al. Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 2011, 29. (suppl; abstr 3062).
77. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Investig Dermatol. 2011;131(8):1735-44. Small study of topical LDE225 that demonstrated both partial and complete regression of primary BCCs in patients with NBCCS with no adverse events.
78. Rudin CM, Jimeno A, Miller WH, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 2011, 29. (suppl; abstr 3014).
79. Siu LL, Papadopoulos N, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2010;28:15s. suppl; abstr 2501.
80. Wolfe CM, Green WH, Cognetta Jr AB, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg. 2012;38(11):1863-6.
81. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173-8. First report of acquired resistance to treatment with a SMO inhibitor.
82. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572-4. Detailed translational report of acquisition of a novel SMO mutation as a possible mechanism of resistance to vismodegib and in vitro data to suggest this is may be due to alterations in drug binding.
83. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324-5.
84. Rudin CM. Vismodegib. Clin Ca Res. 2012;18(12):3218-22.
85. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71:435-44. Important translational article detailing possible mechanisms of resistance to SMO inhibitors and exploring second generation SMO inhibitors in vitro.
86. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2:51-70. Concurrent translational work exploring multiple possible mechanisms of resistance to SMO inhibitors and combinatorial therapy in vitro.
87. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388-99.
88. Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455-60.